1. Home
  2. Browse Decisions
  3. F.4th
  4. 66 F.4th
  5. 66 F.4th 952 (2023)
 

AMGEN INC. v. SANDOZ INC.

2022-1147 2022-1149 2022-1150 2022-1151.

66 F.4th 952 (2023)

AMGEN INC., Plaintiff-Cross-Appellant v. SANDOZ INC., Zydus Pharmaceuticals (USA) Inc., Defendants-Appellants Mankind Pharma Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Limited, Macleods Pharmaceuticals Ltd., MSN Laboratories Private Ltd., Actavis LLC, Prinston Pharmaceutical Inc., Emcure Pharmaceuticals Ltd., Heritage Pharmaceuticals Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Annora Pharma Private Limited, Hetero USA, Inc., Cipla Limited, Alkem Laboratories Ltd., Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Amneal Pharmaceuticals LLC, Pharmascience Inc., Defendants.

United States Court of Appeals, Federal Circuit.

Decided: April 19, 2023.

Attorney(s) appearing for the Case

Steven J. Horowitz , Sidley Austin LLP, Chicago, IL, argued for plaintiff-cross-appellant. Also represented by Paul J. Rogerson , Julia G. Tabat ; Joshua John Fougere , Washington, DC; Sue Wang , San Francisco, CA; Eric Michael Agovino , Gregory David Bonifield , Christina Nichole Gifford , Dennis J. Smith , Stuart Watt , Wendy A. Whiteford , Amgen Inc., Thousand Oaks, CA; Jeffrey B. Elikan , Michael N. Kennedy , George Frank Pappas , Covington & Burling LLP, Washington, DC; Alexa Hansen , San Francisco, CA.

Maureen L. Rurka , Winston & Strawn LLP, Chicago, IL, argued for all defendants-appellants. Defendant-appellant Sandoz Inc. also represented by Samantha Maxfield Lerner ; Eimeric Reig-Plessis , San Francisco, CA.

Michael Gaertner , Locke Lord LLP, Chicago, IL, for defendant-appellant Zydus Pharmaceuticals (USA) Inc. Also represented by David Brian Abramowitz , Hugh S. Balsam , Carolyn Anne Blessing , August Melcher , Emily Savas .

Before Lourie, Cunningham, and Stark, Circuit Judges.

Sandoz Inc. ("Sandoz") appeals from a decision of the United States District Court for the District of New Jersey holding that claims 3 and 6 of Amgen Inc.'s ("Amgen") U.S. Patent 7,427,638 (the "'638 patent") and claims 1 and 15 of Amgen's U.S. Patent 7,893,101 (the "'101 patent") had not been shown to be invalid as obvious...

Let's get started

Leagle.com

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.

  • Updated daily.
  • Uncompromising quality.
  • Complete, Accurate, Current.

Listed below are the cases that are cited in this Featured Case. Click the citation to see the full text of the cited case. Citations are also linked in the body of the Featured Case.

Cited Cases

  • No Cases Found

Listed below are those cases in which this Featured Case is cited. Click on the case name to see the full text of the citing case.

Citing Cases